Company Profile

Sierra Sciences Inc
Profile last edited on: 5/20/19      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1999
First Award
2003
Latest Award
2003
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

250 South Rock Boulevard Suite 130
Reno, NV 89502
   (775) 856-9500
   info@sierrasci.com
   www.sierrasci.com
Location: Single
Congr. District: 02
County: Washoe

Public Profile

Sierra Sciences, Inc. (SSI) is a biotechnology company organzied around development medicines and therapies that could reverse the effects of human aging; enabling people to live longer lives, with health and vigor, free of many of the debilitating effects of old age. At the forefront of efforts to uncover the genetic factors that determine human lifespan and design appropriate interventions to extend and enhance human lifespan and healthspan. The effort hasbeen to develop products to include telomerase inducing chemicals that activate the telomerase gene without killing the cells: a medicine that will activate the expression of telomerase in normal somatic cells. SSI's founder and Vice President Research & Development, Dr. William H. Andrews, was one of the principal discoverers of the telomerase gene. He was awarded 2nd place as "National Inventor of the Year" in 1997 for this discovery, and his name appears on numerous related patents and publications. Under Dr. Andrews' direction, SSI has discovered and filed additional patent applications on many key elements of the transcriptional regulation of telomerase, including DNA transcription factor binding sites and transcription factors. SSI has pursued multiple approaches towards its goal of transiently expressing telomerase in normal cells, including high-throughput screening and other drug discovery efforts.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2003 1 NIH $100,000
Project Title: Purification of hTERT promoter Site C binding protein

Key People / Management

  Richard Offerdahl -- COO

  Pierluigi Zappacosta -- CEO

  William Andrews -- Founder and VP of Research

Company News

There are no news available.